Leukemia
Cyclosporine Modulation of drug resistance with Pravastatin, Etoposide, and Mitoxantrone for Relapsed or Refractory AML (2409)
Cyclosporine Modulation of Drug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01342887
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Investigator: Oliver Press, M.D.; Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01290549
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia (CML); Status: Recruiting; Study ID: NCT00686218
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Recruiting; Study ID: NCT00408005
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia
Investigator: Fred Appelbaum, MD; Conditions: Acute Lymphoid Leukemia; Status: Recruiting; Study ID: NCT00558519
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Investigator: Vivian Oehler, MD; Conditions: Acute Lymphoid Leukemia (ALL), Chronic Myeloid Leukemia (CML); Status: Recruiting; Study ID: NCT01207440
COG - Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group Wide Study
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Closed; Study ID: NCT00103285
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT00895934
Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT00795002
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT01031368
A Phase 1, Dose Escalation Study of Plerixafor in combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia
Investigator: Pamela Becker, MD, PhD; Conditions: De Novo Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT00990054
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome
Investigator: Pamela Becker, MD, PhD; Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS); Status: Recruiting; Study ID: NCT01101880
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia (CLL); Status: Recruiting; Study ID: NCT01188681
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT01141725
A Phase II Trial of Azacitidine plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Older patients with Previously Untreated Non-M3 Acute myeloid Leukemia
Investigator: Fred Appelbaum, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT00658814
A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute myelogenous Leukemia
Investigator: Fred Appelbaum, MD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Recruiting; Study ID: NCT00840177
A Randomized Trial of Maintenance Versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL) , Phase III
Investigator: Fred Appelbaum, MD; Conditions: Acute Promyeloid Leukemia (APL); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT00492856
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Investigator: Bart Scott, MD; Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML); Status: Recruiting; Study ID: NCT00528983
Phase 2 Study of the AKT Kinase inhibitor MK-2206 in Patients with Relapsed Refractory Acute Myelogenous Leukemia
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia (AML);; Status: Recruiting; Study ID: NCT01253447
A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Negative Precursor B-cell Acute Lymphoblastic Leukemia (ALL)
Investigator: Fred Appelbaum, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Recruiting; Study ID: NCT00945815
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01398462
A Phase II Study of ATRA, Arsenic Trioxide, and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia
Investigator: Fred Appelbaum, MD; Conditions: Acute Promyeloid Leukemia (APL); Status: Recruiting; Study ID: NCT00551460
A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)
Investigator: John Pagel, MD, PhD; Conditions: Chronic Lymphoid Leukemia (CLL); Status: Closed; Study ID: NCT00845104
A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma; Status: Recruiting; Study ID: NCT00476047
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies Or In Combination With Dasatinib In Chronic Myeloid Leukemia (CML)
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Recruiting; Study ID: NCT00953758
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
Investigator: John Pagel, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00839982
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01120457
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations
Investigator: Elihu Estey, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00989261
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies
Investigator: Ajay K. Gopal, MD; Conditions: Lymphoma; Status: Recruiting; Study ID: NCT01165112
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Recruiting; Study ID: NCT01300247
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Investigator: Fred Appelbaum, MD; Conditions: Acute Lymphoblastic Leukemia; Status: Recruiting; Study ID: NCT00792948
Join Us On